Skip to main content

Research News

 

Clinical courses

  • Novel Approach for Lymph Node Metastasis Treatment

    Researchers at Tohoku University have discovered a new approach for treating lymph node metastasis. Anticancer drugs are administered directly into the LNs under ultrasound guidance (Lymphatic Drug Delivery System or LDDS) to target sentinel lymph nodes (LNs) and generate antitumor effects locally, preventing distant metastasis. This approach not only improves the anticancer effect but also reduces the nasty side effects commonly associated with systemic chemotherapy.

  • A universal coronavirus vaccine could save billions of dollars if ready before next pandemic

    A new study suggests once developed, having a universal vaccine in advance of the next coronavirus epidemic/pandemic can save up to 7 million hospitalizations and 2 million deaths even when it is the only intervention being implemented and its efficacy is as low as 10%.

  • mRNA technology could be possible treatment for rare diseases

    By exploiting the technology used in Covid-19 vaccines, a team led by UCL, King’s College London and Moderna scientists has created an effective therapy for a rare disease, in a study in mice, demonstrating the technology’s potential therapeutic use in people.

  • European Commission Approves Pfizer TALZENNA in Combination with XTANDI for Adult Patients with Metastatic Castration-Resistant Prostate Cancer

    Pfizer Inc announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. With this approval, TALZENNA is now the first and only PARP inhibitor licensed in the European Union for use with XTANDI for patients with mCRPC, with or without gene mutations.

  • Mayo Clinic Platform and Techcyte announce a strategic collaboration to transform the global practice of pathology

    Mayo Clinic Platform, a collaborative ecosystem for healthcare innovation, and Techcyte, a world leader in AI-based digital pathology, are working together to transform the global practice of pathology through the creation of a digital pathology platform.

  • Study shows liraglutide results in increased insulin sensitivity independent of weight loss

    A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity.

  • Researchers identify why cancer immunotherapy can cause colitis

    Researchers at the University of Michigan Health Rogel Cancer Center have identified a mechanism that causes severe gastrointestinal problems with immune-based cancer treatment.

    They also found a way to deliver immunotherapy’s cancer-killing impact without the unwelcome side effect.

  • Calcium Channel Blockers Key to Reversing Myotonic Dystrophy Muscle Weakness, Study Finds

    New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these symptoms in animal models of the disease. The researchers believe this class of drugs, widely used to treat a number of cardiovascular diseases, hold promise as a future treatment for DM1.

  • Scientists Use Organoid Model to Identify Potential New Pancreatic Cancer Treatment

    A drug screening system that models cancers using lab-grown tissues called organoids has helped uncover a promising target for future pancreatic cancer treatments, according to a new study from researchers at Weill Cornell Medicine.

  • Beyfortus approved in China for the prevention of RSV disease in infants

    AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) in neonates and infants entering or during their first RSV season. Beyfortus is anticipated to be available during the upcoming 2024-2025 RSV season.

Subscribe to Research News